We serve Chemical Name:N,N-dimethyl-1-(1-methylindol-3-yl)methanamine CAS:52972-61-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:N,N-dimethyl-1-(1-methylindol-3-yl)methanamine
CAS.NO:52972-61-9
Synonyms:Dimethyl-(1-methyl-indol-3-ylmethyl)-amin;3-(N,N-dimethylaminomethyl)-1-methylindole;1-methyl-3-dimethylaminomethylindole;dimethyl-(1-methyl-indol-3-ylmethyl)-amine;1-methylgramine
Molecular Formula:C12H16N2
Molecular Weight:188.26900
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:290.9ºC at 760mmHg
Density:1g/cm3
Index of Refraction:1.553
PSA:8.17000
Exact Mass:188.13100
LogP:2.23990
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like Dimethyl-(1-methyl-indol-3-ylmethyl)-amin chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-methylgramine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-(N,N-dimethylaminomethyl)-1-methylindole Use and application,Dimethyl-(1-methyl-indol-3-ylmethyl)-amin technical grade,usp/ep/jp grade.
Related News: This is very visible in herbal medicines in which the API is frequently a combination of several mixtures and/or substances which when used together cause pharmacological activity on the body. N,N-dimethyl-1-(1-methylindol-3-yl)methanamine manufacturer This is very visible in herbal medicines in which the API is frequently a combination of several mixtures and/or substances which when used together cause pharmacological activity on the body. N,N-dimethyl-1-(1-methylindol-3-yl)methanamine supplier This is very visible in herbal medicines in which the API is frequently a combination of several mixtures and/or substances which when used together cause pharmacological activity on the body. N,N-dimethyl-1-(1-methylindol-3-yl)methanamine vendor A Phase 1/2 trial of the combination therapy has been fully enrolled, and the preliminary efficacy and safety data was presented at The American Society of Hematology (ASH) Annual Meeting in December 2018. N,N-dimethyl-1-(1-methylindol-3-yl)methanamine factory A Phase 1/2 trial of the combination therapy has been fully enrolled, and the preliminary efficacy and safety data was presented at The American Society of Hematology (ASH) Annual Meeting in December 2018.
